Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 16
- 1 March 2009
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 182 (5), 2919-2928
- https://doi.org/10.4049/jimmunol.0803645
Abstract
Human papillomavirus (HPV) type 16 infects the epithelial layer of cervical mucosa and is causally associated with the generation of cervical cancer. Langerhans cells (LC) are the resident APCs at the site of infection and therefore are responsible for initiating an immune response against HPV16. On the contrary, LC exposed to HPV16 do not induce a specific T cell immune response, which leads to the immune evasion of HPV16. Demonstrating that TLR7 and TLR8 are expressed on human LC, we hypothesized that imidazoquinolines would activate LC exposed to HPV16, leading to the induction of an HPV16-specific cell-mediated immune response. Surprisingly, both phenotypic and functional hallmarks of activation are not observed when LC are exposed to HPV16 virus-like particles and treated with imiquimod (TLR7 agonist). However, we found that LC are activated by 3M-002 (TLR8 agonist) and resiquimod (TLR8/7 agonist). LC exposed to HPV16 virus-like particles and subsequently treated with 3M-002 or resiquimod highly up-regulate surface activation markers, secrete proinflammatory cytokines and chemokines, induce CCL21-directed migration, and initiate an HPV16-specific CD8+ T cell response. These data strongly indicate that 3M-002 and resiquimod are promising therapeutics for treatment of HPV infections and HPV-induced cervical lesions.Keywords
This publication has 50 references indexed in Scilit:
- Functional Specializations of Human Epidermal Langerhans Cells and CD14+ Dermal Dendritic CellsImmunity, 2008
- TLR7 and TLR8 as targets in cancer therapyOncogene, 2008
- Blood-derived dermal langerin+ dendritic cells survey the skin in the steady stateThe Journal of Experimental Medicine, 2007
- The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cellsThe Journal of Experimental Medicine, 2007
- Tumoricidal activity of TLR7/8-activated inflammatory dendritic cellsThe Journal of Experimental Medicine, 2007
- The Functional Effects of Physical Interactions among Toll-like Receptors 7, 8, and 9Published by Elsevier BV ,2006
- Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κB Activation by Toll-like Receptor 4Published by Elsevier BV ,2003
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cellsEuropean Journal of Immunology, 1998
- Human papillomaviruses in the pathogenesis of anogenital cancerVirology, 1991